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Background: Cerebral infarction due to thrombosis leads to the most common type of stroke and a likely cause of
age-related cognitive decline and dementia. Endothelial nitric oxide synthase (eNOS) generates NO, which plays a
crucial role in maintaining vascular function and exerting an antithrombotic action. Reduced eNOS expression and
eNOS polymorphisms have been associated with stroke and Alzheimer’s disease (AD), the most common type of
dementia associated with neurovascular dysfunction. However, direct proof of such association is lacking. Since
there are no reports of complete eNOS deficiency in humans, we used heterozygous eNOS+/- mice to mimic partial
deficiency of eNOS, and determine its impact on cerebrovascular pathology and perfusion of cerebral vessels.
Results: Combining cerebral angiography with immunohistochemistry, we found thrombotic cerebral infarctions in
eNOS+/- mice as early as 3–6 months of age but not in eNOS+/+ mice at any age. Remarkably, vascular occlusions in
eNOS+/- mice were found almost exclusively in three areas: temporoparietal and retrosplenial granular cortexes, and
hippocampus this distribution precisely matching the hypoperfused areas identified in preclinical AD patients.
Moreover, progressive cerebral amyloid angiopaphy (CAA), blood brain barrier (BBB) breakdown, and cognitive
impairment were also detected in aged eNOS+/- mice.
Conclusions: These data provide for the first time the evidence that partial eNOS deficiency results in spontaneous
thrombotic cerebral infarctions that increase with age, leading to progressive CAA and cognitive impairments.
We thus conclude that eNOS+/- mouse may represent an ideal model of ischemic stroke to address early and
progressive damage in spontaneously-evolving chronic cerebral ischemia and thus, study vascular mechanisms
contributing to vascular dementia and AD.
Keywords: Endothelial nitric oxide synthase (eNOS), Cerebral chronic hypoperfusion, Cerebral dysfunction,
Thrombosis, Microvessel occlusion, Cerebral microinfarction, Vascular dementia, Cerebral amyloid angiopathy (CAA)Background
Nitric oxide (NO) synthesized in endothelial cells from
L-arginine by endothelial nitric oxide synthase (eNOS) is
the major source of NO in brain vessels and an important
signaling molecule in vasculogenesis [1–3], cerebral blood
flow regulation [3, 4], atherosclerosis and thrombosis
[5–8], and amyloid-beta (Aβ) production [9–12]. Thus, in-
tact endothelial function via NO confers key homeostatic* Correspondence: fliao@uthsc.edu
†Equal contributors
1Departments of Pharmacology, University of Tennessee Health Science
Center, 874 Union Avenue/Crowe 401, Memphis, TN 38163, USA
Full list of author information is available at the end of the article
© 2015 Tan et al. This is an Open Access artic
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/balance in normal brain physiology, which raises the
possibility that endothelial dysfunction associated with
deficiency of eNOS and endothelial NO causes cerebro-
vascular pathology and neurological disease. Indeed,
eNOS gene polymorphisms have been reported to be
associated with carotid atherosclerosis [13], ischemic heart
and brain [14–16] and possibly, with Alzheimer’s disease
(AD) [17]. Correlations between eNOS polymorphisms
and decreased NO bioavailability or endothelial
dysfunction have also been reported [13, 18, 19], andle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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AD brain [20].
The importance of eNOS in the cardiovascular system
was demonstrated in animal models [21]. Targeted deletion
of eNOS was shown to cause spontaneous hypertension
and exacerbate stroke outcome [3, 4, 21, 22]. In addition,
multiple hematologic abnormalities [5, 7], cerebral arteri-
olar hypertrophy [4], renal thrombotic microangiopathy
[8] and myocardial infarction [2, 6] have all been reported
in eNOS-deficient mice. Remarkably, neither spontan-
eously evolving microinfactions nor gross anatomical/
histological changes in brain vasculature were observed in
these mice [4, 22]. eNOS polymorphisms and haplotypes,
however, have been reportedly associated with increased
risk of cerebral small-vessel disease as well as silent brain
infarction in humans [14, 15]. It should be underscored
that the vast majority of work revealing pivotal roles of
eNOS in pathophysiology has been conducted on young
eNOS-/- mice.
Remarkably, there are no reports of complete eNOS
deficiency in humans, caution should be taken when
extrapolating conclusions to humans based on data
obtained in eNOS-/- mice. Heterozygous eNOS+/- mice,
however, constitute an ideal model to begin to explore a
possible role of partial eNOS deficiency in neurovascular
pathology. Moreover, since aging is an important risk
factor for cerebrovascular dysfunction and AD [23–26],
it remains critical to determine whether aged eNOS+/-
mice present histological and/or functional deficits
that may be conclusive to stroke and AD. To address
these questions, we combined immunohistochemistry
with cerebral fluorescein isothiocyanate (FITC)-dextran
microangiography and thus identify potential changes in
both brain tissue and vessels in aged (18 months) and
young (6 months) eNOS+/- when compared with litter-
mate eNOS+/+ mice.A
Fig. 1 a Reduced eNOS protein expression in heterozygous mice. eNOS im
of each genotype. Bars represent mean ± s.e.m. b Mean arterial pressure (M
(DBP). eNOS+/- mice have a propensity to develop hypertension but blood
eNOS+/+ mice. P = 0.02 by Student’s t-test. n = 10 animals of each genotypeResults
eNOS expression, blood pressure, and cerebral
microvessel density
Consistent with previous reports [4, 22], both young
(6 months) and aged (18 months) eNOS+/- mice had lower
levels of eNOS protein in brain tissue and a normal range
of blood pressure (Fig. 1a and b, respectively). Interest-
ingly, immunohistochemistry showed a higher microvessel
density in hippocampus but not in cerebral neocortex in
aged eNOS+/- mice when compared with their littermate
wild-type (eNOS+/+) or young eNOS+/- mice (Additional
file 1: Figure S1).
Spontaneous cerebral thrombosis and microinfarctions
To evaluate the functionality of the hyperplasic vessels
found in the aged eNOS+/- mice, cerebral fluorescent angi-
ography was performed, which confirmed the immunohis-
tochemical findings of increased microvascular density in
hippocampus. Remarkably, angiography revealed multiple
cortical/subcortical nonperfusion areas in both young and
aged eNOS+/- mice which were not found in littermate
eNOS+/+ (Fig. 2a, b). Moreover, the nonperfusion areas
were more frequent in aged than in young eNOS+/- mice
(Fig. 2c). It must be underscored that we did not observe
nonperfusion areas in eNOS+/+ mice up to 24 months of
age. Strikingly, most nonperfusion lesions in aged eNOS+/-
mice were bilateral (Fig. 2b). These lesions were not uni-
formly located throughout the brain but primarily re-
stricted to rather defined areas (in frequency order):
parietal association, temporal association and retrosplenial
granular cortexes, hippocampus and thalamus.
In addition, we observed markedly higher FITC signal
in the microvessels surrounding the larger nonperfusion
areas (Fig. 2d), suggesting a compensatory vascular dila-
tion presumably due to more severe ischemia in these
older animals than in younger mice. While mostB
munoblotting of 20 μg of total brain lysates. **P < 0.01. n = 4 animals
AP) were calculated based on the measured systolic (SBP), diastolic
pressure is within normal range compared to age-matched wild-type
. Bars represent mean ± s.e.m
Fig. 2 Multiple cerebral occluded lesions in eNOS+/- mice. a, b Representative FITC-dextran angiographic micrographs in young (a) and aged
eNOS mice (b). Arrows indicate infarctions in hippocampus; red double arrows, bilateral lesions; asterisks, parietal association cortex; daggers,
retrosplenial granular cortex; arrowheads, temporal association/temporoparietal cortexes. Scale bars: 100 μm (a) and 500 μm (b). c Quantification
of the number of cerebral nonperfusion lesions/infarctions per mouse. **P < 0.0005. n = 4–6 mice each genotype. Bars represent mean ± s.e.m.
d Representative FITC-dextran angiographic micrographs with DAPI counterstaining. Scale bars: 100 μm. White arrow indicates a nonperfusion
lesion. e Representative angiograph shows multiple cerebral occluded lesions in thalamus (double arrows). Scale bar: 1 mm
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500 μm) and the cortical lesions rarely extended beyond
the outer half of cortex, some thalamic lesions were up
to 1.5 mm in diameter (Fig. 2e). Interestingly, these non-
perfusion lesions were rarely found in sections without
hippocampal involvement (i.e., the anterior portion of
the brain), underscoring the particular vulnerability of
hippocampal formation and function to partial eNOS
deficiency.
To determine whether nonperfusion areas were due to
vessel obstruction or an actual loss of blood vessels, we
combined cerebral fluorescent angiography with immuno-
fluorescent staining using CD31 and GluT1. Owing to
thick brain sections (100 um) from FITC-dextran perfused
brains, immunostaining signals were much weaker (Fig. 3aand b) as compared to formalin-fixed tissue sections
(40 μm). To our surprise, CD31-positive vessels with di-
ameters of 5–20 μm were largely present within nonperfu-
sion areas (Fig. 3b, c), suggesting that vessel loss does not
critically contribute to the nonperfused areas found in
eNOS+/- mice. This was confirmed by another vascular
marker GluT1 (Fig. 3d), though displaying a discontinued
profile. These findings are consistent with the fact that
microvessel density remains unchanged in neocortex in
aged eNOS+/- mice.
In coronal sections, H & E staining revealed markedly
reduced cellularity and necrosis in the core of lesion in
eNOS+/- mice (12 months) (Fig. 4a), despite marked gliosis
(GFAP/astroglias and Iba-1/microglias) (Fig. 4b). The
nonperfusion areas detected in eNOS+/- brains followed







FITC + CD31 + DAPI D
eNOS+/-
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Fig. 3 Immunohistochemistry of CD31/GluT1 and DAPI on FITC-dextran-perfused brain sections in 18-month old eNOS+/+ (a) and eNOS+/-
(b) mice. a Parietal cortex; Scale bar: 100 μm. b Parietal cortex; Scale bar: 50 μm. c Hippocampus; Scale bars: 100 μm (left panel) and 20 μm
(right panels). d Representative images of GLuT1 and DAPI on FITC-dextran-perfused brain sections corresponding to a nonperfusion lesion.
Scale bar: 20 μm
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farcts: sharply delineated microscopic regions of cellular
death or tissue necrosis, sometimes with cavitation [27].
Moreover, different stages of microinfarcts based on the H
& E histology were detected in eNOS+/- brain at various
ages; the multiple pale lesions detected in older mice most
likely revealed chronic lesions of late staged infarcts, pre-
sumably with the damaged tissue phagocytized (Fig. 4a,
right panel). No similar lesions at any stage were detected
in eNOS+/+ mice at all ages.
Next, to elucidate the cause(s) of vascular obstruction,
we determined the presence of intravascular thrombus.
Immunohistochemistry of fibrinogen/fibrin confirmed
multiple cortical and subcortical intravascular micro-
thrombi blocking the vessels in aged eNOS+/- mice
(Fig. 4c) and, to a lesser degree, in young eNOS+/- mice. In
sharp contrast, microthrombi were never detected in
either aged or young eNOS+/+ mice (data not shown).
Some intravascular thrombi were much smaller than the
lumen of the arterioles, but they were not washed out by
transcardial perfusion during tissue preparation (Fig. 4c,
right lower panels), indicating that these in situ mural
thrombi were due to thrombosis rather than thrombo-
embolism. The presence of continuous strings of
fibrinogen-positive signal along the vessels also supports
the occurrence of thrombosis.CAA, blood brain barrier (BBB) breakdown, and cognitive
dysfunction
We and others have found BACE1 upregulation and
elevated levels of soluble Aβ in young adult eNOS-/- brain
(4 months) [9–12]. We then sought to determine amyloid
deposition in older mice. In aged eNOS+/- mice, we found
significant cerebral amyloid angiopathy (CAA) that
showed dense Aβ deposits within and surrounding the
vessel walls of the arterioles in cerebral pia mater and
parenchyma (Fig. 5a-c) as well as in the hippocampi
(Fig. 5d). CAA was also found in the capillaries reaching
the temporoparietal cortex, hippocampal formation,
amygdala, hypothalamus, and striatum (data not shown).
In contrast, CAA was only occasionally found in aged
eNOS+/+. Moreover, while young eNOS+/- mice (8 months)
displayed mild CAA, no evidence of CAA could be found
in young eNOS+/+ mice (data not shown). Detection of Aβ
aggregation by Thioflavine S staining only revealed a diffu-
sive signal in the brains of eNOS+/- mice, rather than as
focal plaques as in 5XFAD mice (Fig. 5e). Quantification of
Aβ immunoreactivity by ELISA in forebrain indicated a
two-fold increase in soluble Aβ40 starting from young aged
eNOS+/- mice (4–6 months) when compared to littermate
controls (Fig. 5f).
To better understand the consequence of cerebral
thrombosis and CAA, we next studied the leakage of
Fig. 4 Molecular and cellular characteristics of the cerebral occluded lesions in parietal cortex in 18 months eNOS+/- mice: partial eNOS deficiency
causes cerebral thrombosis. a Representative images of H & E Staining (6 μm coronal sections). b GFAP/Iba-1 immunohistochemistry on 12
months eNOS brains. Scale bars: 20 μm. c Representative images of fibrinogen/fibrin (red) and/or CD31 (green) immunohistochemistry in 18-
month-old eNOS+/- mice. White arrows indicate a string of fibrinogen/fibrin-positive signals lining with CD31-positive vessels (upper) and individ-
ual fibrinogen clots inside the arterioles (lower, insets). Scale bars: Upper panels: 50 μm; Lower panel: 500 μm (insets, 50 μm)
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shown in the cortex, aged eNOS+/- mice had localized
extravasations of FITC-dextran (150 Kd, Fig. 6a, right
panel) and serum IgG (Fig. 6b, c, Additional file 1:
Figure S2). Locations and distribution of serum IgG
extravasation were well matched with those of nonperfu-
sion areas as demonstrated by angiography in aged
eNOS+/- mice, consistent with the notion that throm-
botic cerebral infarctions and localized BBB breakdown
are pathophysiologically related in the eNOS+/- mouse.
Moreover, vascular smooth muscle cell degeneration
(Fig. 6d) and a greater number of cerebral microhemor-
rhages scattered over bilateral hemispheres (Fig. 6e, f ).
Cerebral thrombosis or microinfarctions likely contrib-
ute to cognitive decline. Recently, a single cortical microin-
farction event induced by penetrating arteriole obstruction
was shown to cause cognitive deficits in mice [28]. We
therefore hypothesized that eNOS partial deficiency-
induced cerebral infarctions have a negative impact oncognitive performance. Consistent with this idea, by water
maze test, we found progressive cognitive deficits in old
eNOS+/- mice compared to eNOS+/+ controls; no signifi-
cant difference found in young mice (6 months) (Fig. 7a).
Moreover, marked neuroinflammation (activated micro-
glias/Iba-1 and astrocytes/GFAP) and neurodegeneration
with cortical atrophy (~20 % reduction of cortical thick-
ness) were detected in 24 months) eNOS+/- mice (Fig. 7b).
Altered molecular profiles
To determine molecular changes in eNOS+/- mice, we
performed qRT-PCR of frontal brain tissue. When com-
pared with littermate controls, eNOS+/- mice showed pro-
gressive changes in genes involved in a variety of
neurovascular processes such as angiogenesis, inflamma-
tion, and BBB transport. Specifically, we found a signifi-
cant increase in the mRNAs of bFGF-2 and MMP2 (but
not VEGF-A or MMP9 or thrombin), ICAM-1, IL-6,
TNF-α and GFAP (but not IL-1β) (Fig. 8a). Interestingly,
4G8+GLUT1+DAPI
A
CD31 + 4G8B C
Cortex ( 4G8 + CD31)




eNOS +/+ eNOS +/-
eNOS +/+ eNOS +/-
eNOS +/-
eNOS +/+ eNOS +/-
Fig. 5 Partial eNOS deficiency promotes CAA. a Representative images of anti-Aβ (4G8, green) and GLUT1 (green) immunohistochemistry on
cerebral cortex (100 X). b, c Representative images of anti-Aβ (4G8, red) and CD31 (green) immunohistochemistry on cerebral cortex (Scale bars:
100 μm) (B) and on hippocampal fissure (C, Scale bars: 50 μm). d Quantification of Aβ-positive arterioles in hippocampal fissure. *P = 0.01; **P < 0.001.
n = 5–6 mice each genotype. e Representative images of double immunohistochemistry in hippocampal fissure. Scale bars, 50 μm. E) Representative
images of Thioflavine S images taken from cortex. f Quantification of forebrain soluble Aβ40 levels by ELISA (Life Technologies, CA, Cat#KMB3481).
n = 5 each genotype
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Lipoprotein receptor-related protein (LRP-1) and receptor
for advanced glycation end products (RAGE) are the two
molecules most closely related to Aβ uptake/clearance
and protein transport across the BBB [29–32]. Altered ex-
pression of either of these capillary endothelial receptor
proteins could indicate a dysfunction of the BBB and its
transport regulation of Aβ. The increased expression of
Abcb1b (ABCB1b, APC transporter) also strongly sug-
gests a disrupted function in BBB transport. In addition,
TGFβ has been extensively studied in terms of its role in
Aβ biogenesis and neuroinflammation [33]. It is thus very
important to study eNOS-regulated TGFβ, which has thus
far been unexplored. Our data show a ~ 2-fold increase in
tgfb1 mRNAs in the eNOS+/- mouse brain. This first find-
ing suggests an involvement of TGFβ −mediated path-
ways in eNOS mice, which warrants future investigation.Finally, biochemical analysis also reveals evidence of
increased BACE1 expression and hyperphosphorylated
tau as well as CNS insulin resistance in aged eNOS+/-
mice (Fig. 8b).
Discussion
The present study reveals, for the first time, the occur-
rence of spontaneous cerebral thrombosis at early age in
eNOS+/- mice (< 6 months). Moreover, these thrombotic
phenomena increase with age, and are accompanied by
progressive CAA detectable from 8 months of age and
cognitive dysfunction detected at old age (18 months).
But, perhaps what is most striking is that we detected
multiple occluded areas/lesions with diameters ranging
from 0.1 to 1.5 mm in three primary areas (i.e., temporo-
parietal and retrosplenial granular cortexes as well as
hippocampus). Each of these regions matches precisely
Fig. 6 Partial eNOS deficiency causes cerebral BBB breakdown and smooth muscle degeneration. a Angiography 60 min after injection of FITC-dextran
(150 Kd), showing diffusive fluorescent signal as an indication of leakage vessels surrounding the occluded area. b Representative images with DAPI
counterstaining shows parietotemporal cortical vascular extravasations of serum IgG (green, white arrowheads) in 18-month-old eNOS+/- mice. Scale bars:
left panel 100 μm (inset, 20 μm). c Quantification of extravasated mouse IgG based on anti-mouse IgG immunoblot analysis. Note less expression of beta
actin in hippocampus (Hipp) than in cortex (Cort). Values are normalized to beta actin (β-actin out of 20 μg total proteins) and expressed as mean ± s.e.m.
*P< 0.05. n= 4 animals each genotype. d Immunofluorescent staining with anti-SMA (red) and/or anti-CD31 (green) antibodies in aged (18 months)
wild-type and heterozygote eNOS mice. Left panels: arterioles in hippocampal fissure; right panel: parietal cortex. Arrows indicate degeneration
of smooth muscle cells. Scale bars, 20 μm. e Representative images of Prussian blue staining (blue) in cortex in aged eNOS+/- mice. Scale bars, 20 μm.
f Quantification of microhemorrhages based on Prussian blue staining **P < 0.0001. n = 5 mice each genotype. Bars represent mean ± s.e.m
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AD patients [34–36], which indicates that the partial
eNOS-deficient mice is a spontaneous model of chronic
hypoperfusion.
Microscopic examination of aging brain sections,
particularly those exhibiting cognitive decline, often
reveal numerous microinfarctions resulting from small
vessel pathologies such as arteriolosclerosis or CAA
[27]. Microinfarctions and ischemic stroke can be in-
duced by thrombosis, which are usually associated
with increased cellularity due to inflammatory infiltra-
tion and gliosis during an acute stage. We observed
reduced cellularity in the cores of occluded lesions
most of time. Based on the neuropathological defin-
ition of sharply delineated microscopic regions of cel-
lular death or tissue necrosis, we believe the occluded
lesions are in fact microinfarctions. The pale regions
(Fig. 4a, right panel) likely represent chronic lesions
(i.e., “old infarcts”), which typically demonstrate cavi-
tation with surrounding fibrillary gliosis. We occa-
sionally detected more freshly looking lesions in the
neocortex, which showed an acute ischemic appear-
ance of red neurons and loss of colorful staining
quality (not shown). Given the high frequency and
widespread distribution pattern in eNOS mice, thesemicroinfarctions predictably contribute to direct dis-
ruption of important cognitive networks.
While these results were fascinating, an important
question remains unanswered: what causes cerebral
thrombosis (and or thrombotic microinfarctions) if there
was no detection of significant changes in the blood
pressures of eNOS+/- mice at all ages. We favor the
hypothesis that chronic partial eNOS deficiency causes
endothelial and platelet dysfunction, which leads to
thrombotic cerebral infarctions. Indeed, vascular and
platelet activity have been found to be compromised in
eNOS-deficient mice [37].
Based on our data on the sequential events of throm-
bosis, CAA and cognitive decline in eNOS+/- mice, we
further propose the following theory: that chronic partial
eNOS deficiency causes endothelial and platelet dysfunc-
tion that ultimately leads to the thrombotic cerebral
infarctions and associated BBB breakdown that facilitate
Aβ production and impair Aβ clearance [38]. Both of
these events promote vascular deposition of Aβ, resul-
ting in vessel tortuosity (Additional file 1: Figure S3)
which in turn triggers platelet activation and exacerbates
thrombotic cerebral infarction [39]. Although we did not
measure the nitric oxide (NO) content in the brain of
eNOS+/- mice, reduced levels of systemic NO in all
Fig. 7 a Cognitive functions in heterozygous eNOS knockout (eNOS+/-) mice. Spatial learning and memory evaluated by water maze tests reveals
no significant differences between young (6-month-old) eNOS+/- mice and their littermate wild-type (eNOS+/+) mice (n = 10 each genotype), but
severe impairment in aged eNOS+/- mice when compared to eNOS+/+ mice (n = 18 each). Data are presented as means ± SEM. **P <0.005
when eNOS+/- 18months group was compared to that of the littermate eNOS+/+ mice. b Representative images of GFAP and Iba-1 double
immunohistochemistry. White arrowheads indicate activated microglias. Scale bars: 50 μm form the left panels and 25 μm for the right panels.
c Schematic summary of the relative locations of the identified occluded lesions (black) and CAA (red) in old eNOS+/- mice
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notypes detected in these mice as compared to eNOS+/+
and eNOS-/- littermates [40–44], with one exception
[45]. Thus, it is generally believed that the phenotypes
observed in eNOS-deficient mice are due to the reduced
NO levels/functions.
It should be noted that our report is the first to use a
mouse model that does not overexpress a mutant amyloid
precursor protein (APP) or presenilin (PS1) gene to de-
velop aberrant Aβ generation and deposition within vessel
walls (presumably via an eNOS-dependent regulatory
mechanism). Moreover, contrary to most FAD models, in-
cluding a recently established APP-PS1 knock-in model
[46], in which amyloid pathology (CAA in particular)
causes cerebral hypoperfusion, our model clearly demon-
strates that chronic hypoperfusion in fact can induce
CAA. The other major differences in our spontaneous
eNOS and FAD models are the degree of CAA and the
composition of mouse versus human Aβ species. The
two-fold increase of Aβ observed in both soluble and
diffusive plaques in eNOS mice probably indicate milder
CAA when comparing to other FAD models (Fig. 5) [47].
However, we did not observe focal Aβ plaques at 24months of age in eNOS+/- mice, which is consistent with
the notion that endogenous mouse Aβ is less aggregable
and do not form plaques. Nevertheless, it may be in-
formative to further compare our eNOS model with
those of FAD’s. Since mouse Aβ is less toxic than
human’s, it may also be important to cross eNOS-
deficient mice with AD mice expressing human FAD
APP mutants to study interplay between chronic hypo-
perfusion and amyloid progression.
Cerebral hypoperfusion has been identified as a
hallmark in the pre-clinical phase of AD, although
whether it plays a causal role in AD pathogenesis
remains unclear. Cerebral Hypoperfusion and CAA are
both invariant features of dementia and AD [48, 49].
Thus we propose that cerebral hypoperfusion/infarction
and CAA form a vicious cycle for vascular dysfunction
and, ultimately, dementia (Fig. 9). This hypothesis is
supported by the anatomically close vicinity of these two
events (Fig. 7a), as well as by the notion that severe
CAA is induced by cerebral cortical microinfarctions in
humans [50]. Given that FAD mutations were only
detected in < 2 % of AD cases, and hypoperfusion was







Fig. 8 Molecular evidence of neuroinflammation and impaired insulin resistance and BBB transport. a Quantitative qRT-PCR of frontal brain tissue.
b Western blot of frontal brain lysates (20 μg). Gene names used are Mmp2: MMP2; Vegfa: VEGFa; Fgf2: FGF2; Il1b: IL-1 β; Tnf: TNF-1α; Gfap: GFAP;
Tgfb1: TGF-1β; Ager: RAGE; Abcb1b: ABCB1B; Rest: REST
SAD-Metabolic Syndrome
Aging, ApoE, hypertension, diabetes, stroke
Reduced eNOS/NO bioavailability
Chronic Hypoperfusion
Temporoparietal cortex,   Hippocampi, Cingulate
Reduced CBF
Microvascular occlusion, CAA, BBB leakage/neuroinflammation 
Vicious Cycles
Cognitive Deficits
Fig. 9 Schematic demonstration of a “vicious cycle” hypothesis. We
believe that chronic cerebral hypoperfusion and aberrant generation
of amyloid are the two key components forming the vicious cycles
for vascular dysfunction and dementia. Compared to ischemia-induced
severe hypoperfusion, eNOS-deficiency may result in milder but
more chronic hypoperfusion, pointing to a novel pathophysiological
mechanism in the vascular deficits of AD that ultimately leads to the
aforementioned vicious cycles. SAD: sporadic Alzheimer’s disease;
CBF: cerebral blood flow
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model is more representative of sporadic AD cases and
is predictably useful for studying early pathogenic mech-
anisms. Compared to ischemia-induced severe hypoper-
fusion, eNOS-deficiency may result in milder but more
chronic hypoperfusion, suggesting a novel pathophysio-
logical mechanism in the vascular deficits of AD that
ultimately leads to the aforementioned vicious cycle.
Conclusions
Stroke is the third leading cause of death and an import-
ant cause of age-related cognitive decline and dementia.
However, the development of effective therapies for stroke
and vascular dementia has been limited due to the lack of
suitable animal models [51]. The only non-induced model
that mimics both microvessel and parenchymal changes in
human stroke is the spontaneously hypertensive stroke-
prone rat. Although some susceptibility genes have been
identified [52], this rat line is highly inbred and may be of
limited relevance [53]. Consistent with the previous report
[22], our data reveal an absence of severe hypertension in
eNOS-deficient mice, yet interestingly enough these mice
spontaneously develop cerebral infarctions. Therefore, the
eNOS+/- mouse may represent a spontaneous cerebral
infarction model for stroke and vascular dementia, best fit
Tan et al. Molecular Neurodegeneration  (2015) 10:24 Page 10 of 13to understand pathophysiological mechanisms that would
assist in developing novel preventative therapeutic strat-
egies. Stroke is an important risk factor for AD [24–26].
Our most striking finding is that partial eNOS deficiency-
induced cerebral infarctions match well with the patterns
of cerebral blood flow distribution in AD patients [34–36].
This suggests that the eNOS deficient mouse may also
represent a model for sporadic AD, which would greatly
improve our understanding of AD etiology and ultimately




eNOS+/- and littermate eNOS+/+ mice were derived from
interbreeding eNOS+/- and eNOS+/+ mice by using
eNOS-/- mice (NOS3tm1Unc/J Jackson Laboratory, Bar
Harbor ME). Each mouse was genotyped.
Cerebral fluorescent angiography and tissue collection
Cerebral fluorescent angiography was performed as de-
scribed in detail elsewhere [54]. Briefly, FITC-dextran
(2000 Kda; 0.1 mL 50 mg/mL in double-distilled water;
Sigma, St. Louis, MO, USA) was administered intraven-
ously via mouse tail vein. FITC-dextran remained dis-
solved and free in plasma. Two minutes after injecting
FITC-dextran, animals were sacrificed. Brains were rap-
idly removed and placed in 4 % paraformaldehyde (PFA)
in PBS at 4 °C for 24 h and then incubated in 30 %
sucrose in PBS for another 24–36 h at 4 °C. Sequential
coronal sections (100 μm thick) were cut using a
vibratome and kept at −20 °C in an antifreeze solution
(ethylene glycol: glycerol: 0.1 M PBS: double-distilled
water = 1:1:1:1) until further processing. For the perme-
ability test, we injected FITC-dextran (150 Kda; 0.1 mL
50 mg/mL) via tail vein and perfused mice 60 min after
injection before processing for vibratome sections.
Measurement of blood pressure
Systolic (SBP), diastolic (DBP) and mean arterial pres-
sure (MAP) were measured using a noninvasive tail-cuff
method (model XBP 1000, Kent Scientific, Torrington,
CT) as described [55]. All measurements were taken in
the morning, and the first 5 of 25 measurements taken
each day was discarded to obtain data after the mouse
was acclimatized to the equipment. Blood pressure was
measured for 4 consecutive days, and mean values from
individual mice were used for analysis.
Morris Water Maze Test (MWM)
Spatial learning and memory were examined in a MWM
task as we previously described in detail [56]. A video
camera was mounted at the height of 180 cm above the
center of the maze, and all data were recorded with acomputerized video system. Escape latency (finding the
submerged escape platform) and path length to find the
hidden platform were recorded. On day 9, the probe test
was performed by removing the platform and allowing
each mouse to swim freely for 60 s. The total length of
the swim path during the testing period was recorded.
The time that mice spent swimming in the target quadrant
(where the platform was located during hidden platform
training) was measured. For the probe trials, the number
of times the mice crossed where the platform had been
located was also measured and calculated.
Histocytochemistry
Mice were perfused transcardially with ice-cold PBS
followed by ice-cold 4 % PFA in PBS. Then, brains were
removed from the cranium. After postfixation in 4 %
PFA in PBS at 4 °C overnight, brains were incubated in
30 % sucrose in PBS for 24–36 h at 4 °C. Brains were
then cut into serial coronal sections (60 μm thick) on a
vibratome. The sections were kept at −20 °C in the anti-
freeze solution until further processing. Perfused or
angiographic brain (i.e., without transcardial perfused
fixation) sections were treated with 0.3 % triton X-100
for 10 min and blocked with 10 % normal goat serum or
10 % BSA for 60 min at room temperature. Then, sam-
ples were incubated with primary antibody diluted in
blocking solution overnight at 4 °C. We used the follow-
ing primary antibodies: beta amyloid 17–24 (4G8)
monoclonal antibody (Covance; Cat# SIG-39220; 1:100),
rat anti-mouse CD31 (BD BioScience; Cat#553370; 1:50),
anti-GluT1 (~54 kDa) rabbit polyclonal antibody
(Millipore; Cat#07-1401; 1:100), rabbit anti-mouse fibrino-
gen/fibrin polyclonal antibody (MyBioSource; MBS315814;
1:700), mouse anti-GFAP (Sigma, G3893; 1:1000), rabbit
anti-SMA (ABCAM, ab5694; 1:100), rabbit anti-Iba-1
(WAKO, #019-19741; 1:500), Anti-phospho-IGF-IRβ
(Tyr1135/1136)/insulin receptor (IR)-β (Tyr1150/1151)
(19H7) and anti-IRβ (Cell Signaling Technology #3024
and #3025), anti-P-Akt (Thr 473) and anti-Akt (Cell
Signaling Technology, #9271 and #9272), mouse anti-
GSK3 β (Ser9) (Cell Signaling Technology #9336) and
anti-GSK-3β (#9315), Tau-5 (Santa Cruz, sc-58860) and
goat anti-mouse IgG (Biolegend; Cat# 40531;). Thiofla-
vine S was obtained from Sigma. Sections were washed
in PBS and incubated with the following secondary
antibodies dilated in blocking solution 60 min at room
temperature: Alexa Fluor 594 goat anti-mouse IgG
(H + L) (Invitrogen; A11032; 1:500) to detect mouse
Aβ, Alexa Fluor 488 or 555 goat anti-rat (Invitrogen;
A1106 and A11057, respectively) 1:500 to detect mouse
CD31, Alexa Fluor 594 goat anti-rabbit IgG (H + L)
(Invitrogen; A11037; 1:500) to detect GluT1 and fi-
brinogen, and DyLight 488-conjugated AffiniPure don-
key anti-goat IgG (H + L) (Jackson ImmunoResearch;
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were washed in PBS and counterstained with DAPI
(Roche Diagnostics, Lot # 70237122, 1:1000). After
washing with PBS three times, sections were mounted on
microscopy slides and covered with Fluoromount-G
(SouthernBiotech, Cat # 0100-01).
Western blot analysis and quantitative real-time RT-PCR
(qRT-PCR)
Western blot analysis was performed as described [10, 12]
using 20 μg of total protein lysates freshly prepared from
the frontal brain tissue. For qRT-PCR, RNA was prepared
using TRIzol (Invitrogen) according to the manufacturer’s
instructions. Single-stranded cDNA was synthesized from
1 μg of total RNA using High Capacity cDNA Reverse
Transcription kits (Applied Biosystems). Quantitative real-
time PCR was performed with RealMasterMix SYBR ROX
(5 Prime) according to the manufacturer’s protocols using
the same rat and mouse GAPDH primers. Primers for
other mouse genes are listed below: Mmp2 taacctg-
gatgccgtcgt/ttcaggtaataagcacccttgaa; Vegfa gttgcctagtgggtg








Assessment of cerebral microvessel structure and function
Cerebral blood vessel density was assessed according to
the point-counting method [57] on FITC-dextran-perfused
sections that were counterstained with DAPI. The number
of point intersections of CD31-positive and FITC-dextran-
perfused profiles was scored in a 100-point grid, which
covered the entire surface of the microscopic field so that
surface area was calculated according to the magnification
used (×100). Vessel density is expressed as the percentage
of brain surface cover with vessels. Measurements were
performed in bilateral CA1 regions including oriens layer,
pyramidal cell layer and radiatum layer hippocampi in 4
sections taken at 0.6 mm intervals (9–10 sections per
brain with 4 sections showing both CA1 region and
cerebral neocortex, ranging from Bregma 1.98 to
Bregma −3.28 mm). To calculate the number of cerebral
infarctions, 9–10 angiographic sections taken at 0.6 mm
intervals (ranging from Bregma 1.98 to Bregma −3.28 mm)
were assessed using fluorescence microscopy under low
magnification (10x), with results being expressed as
arbitrary units (total number of infarctions in 9–10 brain
sections). CAA and vascular smooth muscle cell injury
were determined using CD31 in combination with Aβ
and SMA immunofluorescent staining, respectively. Thepercentage of Aβ positive arterioles in bilateral hippocam-
pal fissures were calculated in 4 hippocampal sections
taken at 0.6 mm intervals (9–10 sections per brain ranging
from Bregma 1.98 to Bregma −3.28 mm with 4 sections
showing hippocampus). Blood–brain barrier breakdown
was evaluated by either extravasations of mouse IgG by
using immunofluorescent stain or deposition of ferric iron
from hemorrhage by using Perl’s Prussian blue staining.
Statistical analysis
Statistical analyses were performed using unpaired two-
tailed or one-tailed Student’s t-test. Data are reported as
mean ± S.E.M. Statistical significance was set at P < 0.05.
Additional file
Additional file 1: Figure S1. Cerebral microvessel density in eNOS+/-
mice. A-C: Representative images of immunofluorescent staining with
anti-CD31 (an endothelial cell marker) antibodies showing vascular
hyperplasia in hippocampal CA1 region in aged (18-month-old) eNOS+/-
mice (A) compared with either their littermate wild-type (eNOS+/+) mice
(B) or young (6-month-old) eNOS+/- mice (C). Scale bar = 20 μm. D and E)
Quantification of CD31-positive microvessel density in 4 sections with
both hippocampus and cerebral cortex taken at 0.6 mm intervals in
young (6-month-old) and aged mice. Results are expressed as mean ±
SEM. *P < 0.005; **P < 0.0005. n = 5–6 animals each genotype. Figure S2.
Vascular extravasations of serum IgG in 18-month-old eNOS+/- mice.
Representative images of mouse IgG immunohistochemistry showing
leakage areas framed by white box indicating extravasated mouse serum
IgG (green). Scale bars: 200 μm (inset, 50 μm). Figure S3. Cerebral infarction
and tortuous cortical arterioles in heterozygous eNOS+/- mice. Cerebral
fluorescein isothiocyanate (FITC)-dextran (green) angiographic micrograms
showing cerebral microinfarcts/nonperfusion areas (A, B, D, and E. asterisks)
in parietal and parietotemporal cortexes with or without surrounding vascular
dilation and/or hyperplasia (arrows) in aged (18-month-old) and young
(6-month-old) eNOS+/- mice. Note that cortical penetrating arterioles are
more tortuous in aged eNOS+/- mice (A and B, arrowheads and inset)
compared with their littermate wild-type (eNOS+/+) mice (C and inset) and
young eNOS+/- (E) and eNOS+/+ (F and inset) mice. Scale bar = 100 μm.
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